

# Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/N897C770ADBEN.html>

Date: May 2021

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: N897C770ADBEN

## Abstracts

Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Novavax Inc (Novavax) discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology and matrix technology. Its pipeline products includes NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated against ebola virus, middle east respiratory syndrome and severe acute respiratory syndrome. The company operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. Novavax is headquartered in Gaithersburg, Maryland, the US.

### Novavax Inc Key Recent Developments

May 10,2021: Novavax Reports First Quarter 2021 Financial Results and Operational **Highlights**

Apr 13,2021: Novavax Announces Leadership Updates

Apr 08,2021: Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference

Mar 30,2021: US study reveals Pfizer-BioNTech and Moderna Covid-19 vaccines reduce infection risk

Mar 01,2021: Novavax reports fourth quarter and full year 2020 financial results and operational highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Novavax Inc - Key Facts  
Novavax Inc - Key Employees  
Novavax Inc - Key Employee Biographies  
Novavax Inc - Major Products and Services  
Novavax Inc - History  
Novavax Inc - Company Statement  
Novavax Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries  
Joint Venture

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Novavax Inc - Business Description  
Other Break-up: Government Contracts  
Performance  
Other Break-up: Grants and Other  
Performance  
R&D Overview  
Novavax Inc - SWOT Analysis  
SWOT Analysis - Overview  
Novavax Inc - Strengths  
Novavax Inc - Weaknesses  
Novavax Inc - Opportunities  
Novavax Inc - Threats  
Novavax Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Novavax Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

May 10, 2021: Novavax Reports First Quarter 2021 Financial Results and Operational Highlights

Apr 13, 2021: Novavax Announces Leadership Updates

Apr 08, 2021: Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference

Mar 30, 2021: US study reveals Pfizer-BioNTech and Moderna Covid-19 vaccines reduce infection risk

Mar 01, 2021: Novavax reports fourth quarter and full year 2020 financial results and operational highlights

Feb 16, 2021: Novavax, SK Bioscience expand Covid-19 vaccine manufacturing deal

Feb 16, 2021: Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021

Jan 22, 2021: Novavax names Madelyn Caltabiano senior vice president, global program management

Jan 15, 2021: Regulatory expert Henrietta Ukwu, M.D. appointed Novavax Chief Regulatory and Quality Officer

Dec 21, 2020: Biopharma Executive Rick Crowley joins Novavax as Chief Operations Officer

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Novavax Inc, Key Facts  
Novavax Inc, Key Employees  
Novavax Inc, Key Employee Biographies  
Novavax Inc, Major Products and Services  
Novavax Inc, History  
Novavax Inc, Subsidiaries  
Novavax Inc, Joint Venture  
Novavax Inc, Key Competitors  
Novavax Inc, Ratios based on current share price  
Novavax Inc, Annual Ratios  
Novavax Inc, Annual Ratios (Cont...1)  
Novavax Inc, Interim Ratios  
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Novavax Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Novavax Inc, Performance Chart (2016 - 2020)

Novavax Inc, Ratio Charts

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/N897C770ADBEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N897C770ADBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970